Metabolic pathways |
14 |
PLA2G10, PNMT, HSD17B1, HMGCR, CYP2C9, EPHX2, LSS, AKR1C3, CBR1, AKR1B1, HSD11B1, PLA2G2A, LTA4H, HPGDS |
PPAR signaling pathway |
11 |
PPARA, APOA2, PPARD, RXRB, RXRA, PPARG, FABP3, FABP4, FABP7, FABP6, NR1H3 |
Arachidonic acid metabolism |
8 |
AKR1C3, CBR1, PLA2G10, CYP2C9, PLA2G2A, EPHX2, LTA4H, HPGDS |
Metabolism of xenobiotics by cytochrome P450 |
8 |
GSTM1, GSTM2, AKR1C2, CBR1, SULT2A1, CYP2C9, HSD11B1, AKR1C1 |
Steroid hormone biosynthesis |
6 |
AKR1C3, AKR1C2, STS, HSD17B1, HSD11B1, AKR1C1 |
Chemical carcinogenesis |
6 |
GSTM1, GSTM2, CBR1, SULT2A1, CYP2C9, HSD11B1 |
Bile secretion |
4 |
SULT2A1, HMGCR, RXRA, NR1H4 |
Insulin resistance |
4 |
NR1H2, PPARA, PIK3R1, NR1H3 |
Hepatitis C |
4 |
PPARA, RXRA, PIK3R1, NR1H3 |
Nonalcoholic fatty liver disease (NAFLD) |
4 |
PPARA, RXRA, PIK3R1, NR1H3 |
Linoleic acid metabolism |
3 |
PLA2G10, CYP2C9, PLA2G2A |
Thyroid cancer |
3 |
RXRB, RXRA, PPARG |
Non-small cell lung cancer |
3 |
RXRB, RXRA, PIK3R1 |